title: [Treatment of erysipelas in Germany and Austria--results of a survey in German and Austrian dermatological clinics].
abstract: BACKGROUND
  Erysipelas is a severe soft tissue infection usually caused by streptococci. The infection is restricted to the dermis and subcutaneous tissues. Treatment with antibiotics is essential. Many different therapeutic regimens are recommended, based mainly on empirical data and only partly proven by clinical studies.
  
  
  METHODS
  Our aim was to evaluate the treatment of erysipelas in Germany and Austria by means of a questionnaire and to derive treatment recommendations from this data.
  
  
  CONCLUSIONS
  The majority of clinics treat patients with erysipelas as inpatients with intravenous antibiotics. The usual first line treatment is group G penicillin (80%). Other choices include amino-penicillins (11%), cephalosporins (16.5%) and anti-staphylococcal penicillins (6.9%) are used. As second line antibiotics macrolides (63.5%), clindamycin (52.5%), penicillins (18.5%), cephalosporins (40%) and fluoroquinolones (20.5%) are mentioned. Carbapenems, tetracyclines, nitroimidazoles, glycopeptides, aminoglycosides, cotrimoxazole, fusidic acid and fosfomycin are used rarely. The median treatment duration is 10 days. Adjuvant measures are anticoagulation, non-steroidal anti-inflammatory agents, dressings, immobilization and treatment of local predisposing factors such as interdigital tinea.
authors.affiliation: Universitäts-Hautklinik Heidelberg. sabine.brennecke@web.de
authors.forename: Sabine
authors.initials: S
authors.lastname: Brennecke
authors.forename: Martin
authors.initials: M
authors.lastname: Hartmann
authors.forename: Helmut
authors.initials: H
authors.lastname: Schöfer
authors.forename: Heinrich
authors.initials: H
authors.lastname: Rasokat
authors.forename: Erwin
authors.initials: E
authors.lastname: Tschachler
authors.forename: Norbert H
authors.initials: NH
authors.lastname: Brockmeyer
mesh_terms: D000554:Ambulatory Care Facilities / Q000706:statistics & numerical data*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001317:Austria / Q000453:epidemiology; D003880:Dermatology / Q000706:statistics & numerical data*; D004363:Drug Utilization / Q000706:statistics & numerical data; D004886:Erysipelas / Q000188:drug therapy* / Q000453:epidemiology*; D005858:Germany / Q000453:epidemiology; D019538:Health Care Surveys; D006801:Humans; D010400:Penicillin G / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D010400:Penicillin G